A detailed history of Creative Planning transactions in Myriad Genetics Inc stock. As of the latest transaction made, Creative Planning holds 9,949 shares of MYGN stock, worth $134,311. This represents 0.0% of its overall portfolio holdings.

Number of Shares
9,949
Previous 9,057 9.85%
Holding current value
$134,311
Previous $221,000 23.08%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 11, 2024

BUY
$23.97 - $28.6 $21,381 - $25,511
892 Added 9.85%
9,949 $272,000
Q2 2024

Aug 15, 2024

BUY
$17.98 - $25.47 $162,844 - $230,681
9,057 New
9,057 $221,000
Q1 2020

May 05, 2020

SELL
$9.78 - $29.53 $87,540 - $264,323
-8,951 Closed
0 $0
Q4 2019

Jan 30, 2020

BUY
$20.93 - $35.1 $14,651 - $24,570
700 Added 8.48%
8,951 $244,000
Q3 2019

Nov 01, 2019

BUY
$22.08 - $47.08 $182,182 - $388,457
8,251 New
8,251 $236,000
Q2 2019

Jul 26, 2019

SELL
$22.67 - $35.0 $170,025 - $262,500
-7,500 Closed
0 $0
Q1 2019

Apr 24, 2019

SELL
$26.93 - $34.7 $11,660 - $15,025
-433 Reduced 5.46%
7,500 $249,000
Q4 2018

Feb 01, 2019

BUY
$27.23 - $45.56 $58,544 - $97,954
2,150 Added 37.18%
7,933 $231,000
Q3 2018

Oct 25, 2018

BUY
$37.57 - $50.34 $217,267 - $291,116
5,783 New
5,783 $266,000
Q1 2018

Apr 18, 2018

SELL
$28.83 - $41.01 $198,754 - $282,722
-6,894 Closed
0 $0
Q4 2017

Jan 17, 2018

SELL
$28.45 - $37.14 $11,067 - $14,447
-389 Reduced 5.34%
6,894 $237,000
Q3 2017

Oct 17, 2017

BUY
$24.01 - $36.2 $174,864 - $263,644
7,283
7,283 $263,000

Others Institutions Holding MYGN

About MYRIAD GENETICS INC


  • Ticker MYGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 80,634,800
  • Market Cap $1.09B
  • Description
  • Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...
More about MYGN
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.